November 26, 2018
Lilly Oncology is known for its exciting pipeline across multiple tumor types and dedication to addressing the unmet needs of people living with cancer. Their perseverance to deliver innovative solutions continues as they trust their retained partnership with The Chase Group to find high caliber talent across two distinct therapeutic areas.
Specifically, Lilly’s Senior Medical Advisor, Global Medical Affairs – Breast Oncology will join the Verzenio® (Abemaciclib) enterprise to lead and manage the global breast medical affairs function for NILEX opportunities across multiple patient populations and initially be focused on developing the global medical plan and strategy for environment shaping of programs leading to commercialization of new indications.
The Medical Advisor, Clinical Development – GI Oncology, will join the Cyramza®(Ramucirumab) enterprise and will have responsibility for the global medical leadership for late phase development in hepatocellular cancer, as well as the global medical leadership of combination studies across a portfolio of early oncology products.
For more information about the ongoing Eli Lilly/Chase partnership, contact Moira Newbanks at 913-663-3100 or email@example.com.